Velia

Amide Technologies Announces Complex Peptide Manufacturing Platform, Raises $16.5M to Expedite Frontier Drug Discovery

Retrieved on: 
星期四, 十二月 14, 2023
Professional Services, Health, Other Professional Services, Other Health, Finance, Pharmaceutical, Biotechnology, Peptide, Dicarboxylic acid, SPPS, Acquisition, DNA, Liraglutide, Organization, Therapy, MIT, Velia, ITA Software, Dulaglutide, Flight, Leuprorelin, Protein, Multimedia, AFPS, Infection, Biology, FDA, General partnership, CIO, Drug design, Structural biology, Goserelin, Hand, Drug discovery, Ginkgo Bioworks, Doctor of Philosophy, Cancer, Diabetes, Type 2, Chemistry, Fine chemical, Amide

Amide Technologies , a biotech that synthesizes challenging peptides, announced today that it has begun commercializing its novel peptide manufacturing platform.

Key Points: 
  • Amide Technologies , a biotech that synthesizes challenging peptides, announced today that it has begun commercializing its novel peptide manufacturing platform.
  • New advances in structural biology, recombinant biologics, and AI-driven technologies have improved drug design and delivery methods, overcoming many previous pharmacokinetic behavior drawbacks of peptides .
  • “Amide delivers on complex peptide orders that other vendors refuse because peptide sourcing shouldn’t stand in the way of discovery,” said Amide CEO Mark Simon, PhD.
  • ITA Software founder and CEO Jeremy Wertheimer is an Amide co-founder and Board Member, alongside MIT Professor of Chemistry Brad Pentelute, PhD.

Velia Therapeutics Appoints Michael York as Chief Business Officer

Retrieved on: 
星期四, 十二月 14, 2023
University, Proteome, Economics, Amylin Pharmaceuticals, Research, SAN, AstraZeneca, Therapy, Patient, Strategic planning, IPO, MBA, MD, Growth, San Diego State University, Fine chemical, Management, Microprotein, Velia, Merck, Orexigen Therapeutics

SAN DIEGO, Dec. 14, 2023 /PRNewswire/ -- Velia Therapeutics, a biotechnology company focused on the discovery and development of a new generation of protein-based therapeutics that address the underlying causes of difficult-to-treat diseases, today announced that Michael York has joined the organization as chief business officer. Mr. York will lead business development, research collaborations and strategic planning to drive growth of the company's microprotein-based pipeline of transformative therapeutics.

Key Points: 
  • Mr. York brings over 30 years of experience leading business development, strategic planning and commercial functions across pharmaceutical and biotech companies
    SAN DIEGO, Dec. 14, 2023 /PRNewswire/ -- Velia Therapeutics, a biotechnology company focused on the discovery and development of a new generation of protein-based therapeutics that address the underlying causes of difficult-to-treat diseases, today announced that Michael York has joined the organization as chief business officer.
  • Mr. York will lead business development, research collaborations and strategic planning to drive growth of the company's microprotein-based pipeline of transformative therapeutics.
  • "I am pleased to welcome Michael to Velia as chief business officer, where he will play a critical role in our portfolio planning efforts to prioritize microproteins that we've identified hidden in the dark matter of the human proteome," said John McHutchison, AO, MD, president and chief executive officer at Velia Therapeutics.
  • Mr. York has more than 30 years of experience in business development, corporate strategy, and commercial leadership across a breadth of therapeutic categories.